What Claril Treats: Main Uses and Benefits

Claril is commonly used to help with eye symptoms linked to common environmental triggers. It is generally applied in addressing conditions presenting with acute episodes of allergic conjunctivitis. Specifically, it is relevant for easing eye itching (pruritus), eye redness (hyperemia), and eye watering (lacrimation), which are symptoms related to physical discomfort.

This medication is commonly used when short-term symptomatic assistance is needed during phases of high exposure to pollen, ragweed, grass, animal hair, and dander. It is relevant in clinical settings marked by temporary physiological imbalance, supporting patients during difficult episodes by easing distress.

“The use of Claril assists with maintaining functional stability when symptoms interfere with routine activities, and contributes to easing the overall symptom load during periods of heightened symptoms.”

It may assist with addressing symptom clusters that may become intense or disruptive, including mild swelling of the eye tissues, which is commonly associated with these acute allergic reactions.

---

Quick Fact: Relief for Itching and Redness

---

Regulatory References

1. NIH DailyMed Drug Information

The eligibility for using Claril (Naphazoline/Pheniramine Ophthalmic Solution) is strictly defined by governmental regulatory authorities based on age thresholds and sensitivity to the active ingredients. Use is established for adults and children 6 years of age and older. All eligibility statements are based on official regulatory labeling.

Eligibility Status	Population/Condition
Absolute Contraindication	Individuals with known hypersensitivity or allergy to Naphazoline, Pheniramine, or any component of the ophthalmic solution.
Restricted/Conditional Use	Children under 6 years of age are restricted and must consult a physician prior to administration.
Restricted/Conditional Use	Patients with specific conditions must consult a physician before use: narrow-angle glaucoma, heart disease, high blood pressure (hypertension), or trouble urinating (e.g., due to an enlarged prostate gland).
Conditional Status	Pregnant or breastfeeding individuals must consult a healthcare provider. The official regulatory label does not establish definitive eligibility for these groups.

The official eligibility profile strictly prohibits use for allergic individuals. It formally defines restricted-use patient populations based on their sensitivity to the decongestant component, particularly those with pre-existing cardiovascular, ocular, and urological conditions, requiring mandatory professional consultation prior to use.

Claril Interactions with other medicines and products

Interaction Scope

Property	Value
Medicinal product categories with documented interactions	Monoamine Oxidase Inhibitors ( MAOIs); Tricyclic Antidepressants; Cardiac Glycosides; Quinidine; Central Nervous System ( CNS) Depressants.
Mechanistic basis of interactions	Sympathomimetic Potentiation (risk of hypertensive reaction); Potentiation of Sedative Effects (additive CNS depression).
Timing-based interaction rules	Mandatory removal of soft contact lenses before application; wait at least 10 to 15 minutes before reinsertion.

---

Interaction Classifications

Property	Value
Interaction severity classification	Contraindicated Combination (with MAOIs); Increased Risk (of cardiac arrhythmias); Potentiation of Sedative Effects.
Regulatory basis	Information is consistent with official labeling from US and international health agencies.

---

Official interaction statements

Co-administration with Monoamine Oxidase Inhibitors ( MAOIs) is officially classified as contraindicated due to the risk of a severe hypertensive crisis. This restriction extends to use within 14 days of stopping MAOI therapy.

• Concomitant use with Tricyclic Antidepressants, Cardiac Glycosides, or Quinidine is associated with an increased risk of cardiac arrhythmias.
• The Pheniramine component may lead to the potentiation of sedative effects when co-administered with CNS depressant medicinal products or Alcohol.
• The administration process requires a mandatory timing separation for soft contact lenses. Lenses must be removed before drops are applied, and reinsertion must be delayed by at least 10 to 15 minutes.

The mechanism of action for this combination product operates via two independent physiological domains. Pheniramine is an H1 receptor antagonist that binds competitively to the Histamine H1 receptors located on sensory nerves and vascular tissue. This interaction functionally disrupts the H1-mediated signal transduction cascade, thereby altering the physiological response driven by the inflammatory mediator histamine.

Simultaneously, Naphazoline is a direct-acting alpha-adrenergic receptor agonist that preferentially activates alpha1 and alpha2 receptors on vascular smooth muscle cells. This agonism initiates an intracellular cascade resulting in muscle contraction and subsequent vasoconstriction of the conjunctival arterioles.

This complementary action influences two independent physiological systems: the neurochemical response and the hemodynamic response. However, continuous alpha-adrenergic stimulation can lead to receptor desensitization and adaptation, a constraint of the mechanism known as tachyphylaxis, where functional response may diminish.

Claril (Naphazoline Hydrochloride/Pheniramine Maleate) is designated strictly for ophthalmic (topical) administration to the eye surface, consistent with its form as an eye solution. The designated dosing schedule is for adults and children aged six years and older.

The standard dose is 1 or 2 drops instilled into the affected eye(s). Application may be repeated up to 4 times daily, provided that doses are separated by at least four hours. The use is temporary, dictated by a critical maximum duration constraint: the solution must not be used for more than 72 consecutive hours (3 days) unless directed by a physician. For children under 6 years of age, use requires consultation with a physician.

Proper administration includes specific conditions. To maintain sterility, the dropper tip must not be allowed to touch the eye or any other surface. If the user wears contact lenses, they must be removed prior to instillation, and reinsertion should be delayed by 10 to 15 minutes. If another topical ophthalmic product is being used, a 5 to 15 minute interval must be observed between the two applications.

Research Evidence / Overview of Studies

Summary of Clinical Findings

Studies were conducted based on a pharmacological hypothesis. Research evaluated whether the compound was associated with changes in pain and inflammation and explored whether the compound was associated with improvements in mobility and short-term symptom changes.

• Phase II Trials: Initial, small-scale trials primarily focused on establishing the safety profile and identifying a suitable dosage range. Initial, small-scale trials noted the compound's safety profile and tolerability observations.
• Phase III Trials: Larger, randomized, controlled trials (RCTs) examined the compound against a placebo over a 12-week period. These studies sought to describe the compound’s effects on key endpoints such as pain scores (measured using the VAS scale) and joint swelling. Trials examined whether the compound was associated with a reduction in the frequency of flare-ups over a specific duration.

---

Combination Therapy Research

Research explored whether the combination of the compound with standard care presented an alternative approach compared to standard care alone. This research aimed to describe the comparative findings when the two treatments were used together.

• Cochrane Review (2022): A systematic review analyzed data from five randomized trials. The review investigated whether adding the compound to existing therapy was associated with a statistically significant difference in patient-reported quality of life compared to placebo addition. Findings were mixed across the included studies.
• Long-term Data: Some follow-up studies extending beyond one year were conducted to monitor the long-term safety of the compound. These studies also investigated whether the compound had a modulating effect on specific markers of the body’s immune response.

---

Pharmacological and Safety Profile

Studies have examined the compound’s profile compared to other common treatments for the condition. Research included assessments of the compound's metabolism and clearance profile.

• Dosage and Administration: The optimal timing for administration was evaluated in trials, with some research focusing on night-time dosing. Different oral formulations were tested to assess bioavailability.
• Adverse Events: Studies documented adverse events, with mild gastrointestinal upset and headache being among the most frequently reported. Monitoring for rare, serious adverse events was conducted throughout the trial phases.
• Specific Patient Groups: Research noted that individuals with pre-existing kidney conditions were generally excluded from or monitored closely in clinical trials.

Common questions about Claril (FAQ)

Q: Is Claril similar to other medicines for [condition type]?

A: Claril is officially classified as an ophthalmic antihistamine and decongestant. This combination formulation is used for eye redness and itching. The official product labeling names other over-the-counter products that contain the identical active ingredients and are used for similar symptomatic relief.

Q: What should I know about taking Claril with food?

A: Claril is an ophthalmic solution, meaning it is applied topically directly to the eye surface and is not meant to be swallowed. Because of this route of administration, drug-food interactions are generally not a documented concern.

Q: Are there common lifestyle changes associated with using Claril?

A: Regulatory documents indicate that caution is advised regarding activities like driving or operating machinery until any temporary blurred vision has resolved. This is due to the potential for side effects such as dizziness or transient blurred vision.

Q: What does it mean if an official document mentions Claril having 'limited data'?

A: The phrase 'limited data' is used in official documents, such as for use during pregnancy, to indicate that human studies in that specific context are either limited or unavailable. This is a standard regulatory statement used when data is insufficient to establish definitive safety or risk.

Q: Does Claril have known issues when taken with popular vitamins?

A: Drug interaction resources often list common vitamins and supplements, such as Vitamin C and Fish Oil, when checking for potential issues with the solution's components. Official resources suggest that individuals may wish to discuss all supplements being used with a healthcare professional.

Q: Why do official sources mention a risk of liver problems with Claril?

A: Official sources advise consultation with a healthcare professional for patients with pre-existing liver impairments, as information on use in these cases is limited. This is a common precaution tied to the metabolism and clearance of medicinal products.

Q: Is Claril a controlled substance?

A: No. Claril (Naphazoline/Pheniramine Ophthalmic Solution) is typically available over-the-counter ( OTC) in the United States. It is not classified as a controlled substance under the Drug Enforcement Administration ( DEA) schedules.

Q: What is the typical time frame before Claril starts working?

A: Evidence from clinical studies suggests the ophthalmic solution can be associated with the start of symptomatic relief, particularly for itching, within minutes of application. The duration of this relief is subject to the individual and the severity of symptoms.

Q: What happens if I forget to take Claril sometimes?

A: This medicine is used on an as-needed basis for the temporary relief of symptoms. As this medicine is used for temporary, symptomatic relief, specific missed dose instructions are generally not provided in consumer information. If symptoms persist, consultation with a healthcare professional is advised.

Q: Can Claril affect driving or operating machinery?

A: Caution is advised regarding driving or operating heavy machinery after using the drops. This is because some users may temporarily experience side effects such as blurred vision or dizziness, which can potentially impact the ability to perform these tasks.

Q: Is it normal to feel a change in sleep patterns while taking Claril?

A: Systemic side effects from the decongestant component, such as nervousness and dizziness, have been reported in official documents. Additionally, the antihistamine component can potentiate (increase the effect of) sedative medications, which may indirectly influence sleep patterns.

Q: What should I do if I think Claril is not working for me?

A: Official product labeling advises that users should stop using the medicine and consult a healthcare provider if eye redness or irritation worsens or persists beyond the maximum stated duration of 72 hours (3 days). This is the standard guidance provided in the product warnings.

Q: Does Claril have interactions with common pain relievers like ibuprofen?

A: Drug interaction resources list common over-the-counter pain relievers such as ibuprofen and acetaminophen as potentially having minor interactions with the ophthalmic solution components. Official resources suggest that individuals may wish to consult a healthcare provider to review any specific concerns.

Q: Is there a generic version of Claril available?

A: Claril is a brand name for the combination of naphazoline and pheniramine. The generic combination of these two active ingredients is available under multiple other brand names and generic formulations that have received regulatory approval.

Q: Are Claril and [another similar sounding drug] the same?

A: A drug's official identity is based on its active ingredients and formulation. The official labeling names other brands with identical ingredients, but confirmation may be sought for similar-sounding names to ensure the correct product is being discussed.

Q: How long does the effect of one dose of Claril typically last?

A: The maximum recommended dosing allows for repeat application after an interval of at least four hours. This interval suggests the potential duration of symptomatic relief. Individual experience may vary based on symptom severity.

Q: Are there any known interactions between Claril and herbal supplements?

A: Interaction checkers based on the official drug components list some herbal supplements as having potential concerns. It is generally advised that individuals inform their healthcare provider about all herbs and supplements they use, as interaction resources may list potential concerns.

Q: Is Claril's purpose related to inflammation?

A: Yes, the product’s dual mechanism is related to the body’s inflammatory response. The antihistamine component, pheniramine, works by blocking histamine, a key substance released by the body that drives the early phase of the allergic inflammatory response.

Q: What are the signs of an allergic reaction to Claril?

A: Official consumer information describes signs of a severe allergic reaction, such as rash, hives, intense itching, swelling of the face, lips, tongue, or throat, or trouble breathing, which may warrant immediate attention.

Q: Do studies suggest Claril is a cure for the condition it treats?

A: No. The official labeling for Claril specifies that it is indicated only for the temporary relief of symptoms like redness and itching associated with minor eye irritation. It is not considered a curative treatment.

Q: What information is needed to determine if Claril is right for someone?

A: Official labeling requires consulting a healthcare provider if a person has certain pre-existing conditions before use. These include conditions such as narrow-angle glaucoma, high blood pressure, heart disease, diabetes, or trouble urinating.

Q: Does Claril interact with grapefruit or grapefruit juice?

A: No major drug-food interactions have been found or officially established specifically for this topical ophthalmic solution. However, patients may wish to discuss all food and beverage consumption with a healthcare professional.

Q: Is Claril studied in people over the age of 65?

A: Official documents state that no well-controlled studies specifically in elderly populations have been conducted. However, the regulatory body has not identified specific usage issues in this age group since the product was marketed.

Q: Is Claril a new drug or has it been available for a long time?

A: The combination product of Naphazoline and Pheniramine was approved for medical use in the United States in 1994. Individual brand and generic formulations have received various FDA approvals since that time.

Q: What happens when Claril is stopped suddenly?

A: The product is intended for short-term, temporary relief. Regulatory documents warn that overuse or use beyond the recommended duration can lead to or intensify a condition called rebound conjunctival congestion, which is characterized by persistent or increased eye redness.

Q: What does the research say about Claril's use in younger adults?

A: Clinical studies often include participants in the age range of younger adults, typically starting at 18 years of age. Since the eligibility criteria cover adults, patients in this age group are considered appropriate for use.

How to Store and Dispose of Claril?

The storage and disposal of Claril (Naphazoline Hydrochloride/Pheniramine Maleate Ophthalmic Solution) are governed by official regulatory instructions focused on maintaining stability, preventing contamination, and ensuring safety.

Storage Requirement	Official Constraint
Temperature & Light	Store at controlled room temperature (20 C to 25 C) and protect from light. Do not freeze.
Container Integrity	Keep the bottle tightly closed in its original container; avoid touching the dropper tip to any surface.
Stability Period	Discard the solution within 28 to 30 days after first opening, regardless of the printed expiration date.
Child Safety	Mandatory: Keep the medicine strictly out of the sight and reach of children.
Disposal	Dispose of unused or expired product via an authorized drug take-back location or by mixing the contents with an undesirable substance before discarding in the household trash.

These official rules ensure the medication retains its integrity and prevent accidental exposure.